Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.
about
Practical guidelines for B-cell receptor repertoire sequencing analysisDistinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Integrated digital error suppression for improved detection of circulating tumor DNANew developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015.Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients.The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma.Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.Evolution of lymphoma staging and response evaluation: current limitations and future directions.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma.Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential.Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas.Epstein-Barr virus-negative diffuse large B cell lymphoma with aberrant expression of CD3 and other T cell-associated antigens: report of three cases with a review of the literature.Clinical Trials in the Genomic Era.Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine.Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignanciesThe evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064).Highly sensitive MYD88L265P mutation detection by droplet digital PCR in Waldenström Macroglobulinemia.Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements.A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival.
P2860
Q28607156-C2CA887A-E4AD-4FC7-A144-101CB5F0FA21Q33851726-AFB632B9-1E46-4387-88B1-CCD9B02E9F95Q34520008-9F206ACC-3ACB-45EE-90EC-E0DC694A1DD2Q35783447-AE1AE322-5963-40B5-8CD7-51820F55D308Q36788133-ED9F4C54-5579-4953-BCDB-8F583D03015DQ37035820-8E542D0C-1364-4CCE-B962-419C47D9C2DFQ37150016-ED93D508-E741-4BD9-A1AA-728A6CE28078Q37417538-B17B1CCB-EA74-49F1-A04C-2B690A251749Q37702797-94D63FDC-D90E-4E79-9D12-B39D102787E4Q37710733-2738ABD5-1520-4B60-BD76-77EF5FF94345Q38664822-9DD11E40-9618-4FC3-AAA2-6FDFED45C9F8Q38671671-D4C98596-4F10-4A34-86FA-7373E06D94B2Q38672646-62A9762F-1C41-47DF-8419-6EB261011685Q38716377-81B217B2-B919-4B88-9661-B8355335CFF7Q38728592-2FB8A36A-F5D2-4A41-A7AE-A165D3D1784BQ38729502-9F6D46BA-9C7F-4507-B00C-49940640FC55Q38811964-33198E2B-E134-49D2-B484-74FE74B58A44Q38901589-2EF68410-0F97-4846-9EB5-30E65461D5E5Q38905607-64CAF128-B40F-42D0-B353-91551B152D6BQ38909384-11C7B5C1-13C6-4438-8B2C-8616B44D4E2AQ38959472-EEB63383-327E-4EA4-8DE8-827D2E21DDE5Q39036785-8AFED888-7F6F-4132-BB95-29463C5D787EQ39135290-CD43AF0E-CB82-4D69-A40C-C775DBFC66C9Q39147488-E591888B-2EBE-4257-9333-F02E543D54ABQ40353159-46A8A0C4-57CB-4B9B-B595-7081DBE0310FQ41001462-F622DB4D-B44D-4DCD-9758-A4909AD843BEQ41471491-A845B2B5-811F-4D13-B9F8-62F84D255B35Q42234608-34CE4C95-79CA-4E03-AC4D-A071986CFC2EQ42348448-12948EE4-E120-4644-B0F7-387E54747BA9Q42421291-5C7175F1-C61C-49AB-8EC7-B0C3DBFBE781Q42643973-8308A09E-087E-42B2-B3AA-8F730A66292EQ47568589-1E95019F-71CF-46A5-AD16-8A96E2C42AF0Q47603352-EF5B7D3C-FCE7-4F5A-A7E3-B154288D2D98Q47873950-39EDA931-B8BD-4C8A-A24F-370164F0D514Q48277300-F6AFE030-1247-494F-AA40-8A67F81779F5Q48649466-153857EC-4731-4716-BA8F-8C1B5F8C4EB6Q52641888-65588AC7-A7E7-4F6B-AAA1-F0EC000FEBD8Q54918383-4366E061-B98E-44E7-B66B-B58D768B464BQ55291290-39D432CD-CEB8-4CEA-AEFA-8832F129A0ABQ55299986-03E22CE5-F7FA-429F-A404-1471141D93F5
P2860
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Noninvasive monitoring of diff ...... in high-throughput sequencing.
@ast
Noninvasive monitoring of diff ...... in high-throughput sequencing.
@en
type
label
Noninvasive monitoring of diff ...... in high-throughput sequencing.
@ast
Noninvasive monitoring of diff ...... in high-throughput sequencing.
@en
prefLabel
Noninvasive monitoring of diff ...... in high-throughput sequencing.
@ast
Noninvasive monitoring of diff ...... in high-throughput sequencing.
@en
P2093
P2860
P50
P1433
P1476
Noninvasive monitoring of diff ...... lin high-throughput sequencing
@en
P2093
Brendan Visser
Chih Long Liu
Cynthia Glover
David Miklos
Florian Scherer
Jason Callahan
Karen S Corbelli
Katherine A Kong
Kazuhiro Takahashi
Maher K Gandhi
P2860
P304
P356
10.1182/BLOOD-2015-03-635169
P407
P577
2015-04-17T00:00:00Z